134 related articles for article (PubMed ID: 26565934)
1. Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective.
Nazareth T; Li N; Marynchenko M; Zhou Z; Chopra P; Signorovitch J; Wu E; Ahmed S; Marvel J; Sasane R
Curr Med Res Opin; 2016; 32(3):405-16. PubMed ID: 26565934
[TBL] [Abstract][Full Text] [Related]
2. Patient and Caregiver Burden Associated With Fragile X Syndrome in the United States.
Vekeman F; Gauthier-Loiselle M; Faust E; Lefebvre P; Lahoz R; Duh MS; Sacco P
Am J Intellect Dev Disabil; 2015 Sep; 120(5):444-59. PubMed ID: 26322391
[TBL] [Abstract][Full Text] [Related]
3. Fragile X syndrome: economic burden and health-related quality of life of patients and caregivers in France.
Chevreul K; Berg Brigham K; Brunn M; des Portes V;
J Intellect Disabil Res; 2015 Dec; 59(12):1108-20. PubMed ID: 26369667
[TBL] [Abstract][Full Text] [Related]
4. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
5. Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe.
Chevreul K; Gandré C; Brigham KB; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Gulácsi L; von der Schulenburg JM; Kanavos P; Persson U; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():43-52. PubMed ID: 27072054
[TBL] [Abstract][Full Text] [Related]
6. The economic burden of fragile x syndrome: healthcare resource utilization in the United States.
Sacco P; Capkun-Niggli G; Zhang X; Jose R
Am Health Drug Benefits; 2013 Mar; 6(2):73-83. PubMed ID: 24991348
[TBL] [Abstract][Full Text] [Related]
7. Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index.
Raspa M; Sacco P; Candrilli SD; Bishop E; Petrillo J
J Intellect Disabil Res; 2016 Sep; 60(9):844-55. PubMed ID: 26929037
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
9. Health and economic consequences of fragile X syndrome for caregivers.
Bailey DB; Raspa M; Bishop E; Mitra D; Martin S; Wheeler A; Sacco P
J Dev Behav Pediatr; 2012; 33(9):705-12. PubMed ID: 23117595
[TBL] [Abstract][Full Text] [Related]
10. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
11. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States.
Patel C; Pilon D; Gupta D; Morrison L; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2022; 25(1):792-807. PubMed ID: 35635250
[TBL] [Abstract][Full Text] [Related]
12. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries.
Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Joshi K; Lefebvre P
Curr Med Res Opin; 2021 Oct; 37(10):1811-1819. PubMed ID: 34281472
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
[TBL] [Abstract][Full Text] [Related]
15. Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study.
Haessler F; Gaese F; Huss M; Kretschmar C; Brinkman M; Peters H; Elstner S; Colla M; Pittrow D
BMC Psychiatry; 2016 Sep; 16(1):318. PubMed ID: 27612457
[TBL] [Abstract][Full Text] [Related]
16. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus.
Guo JJ; Gibson JT; Gropper DM; Oswald SL; Barker KN
Am J Manag Care; 1998 Oct; 4(10):1433-46. PubMed ID: 10338736
[TBL] [Abstract][Full Text] [Related]
17. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.
Insinga RP; Itzler RF; Pellissier JM
Pharmacoeconomics; 2007; 25(2):155-69. PubMed ID: 17249857
[TBL] [Abstract][Full Text] [Related]
18. The High Direct Medical Costs of Prader-Willi Syndrome.
Shoffstall AJ; Gaebler JA; Kreher NC; Niecko T; Douglas D; Strong TV; Miller JL; Stafford DE; Butler MG
J Pediatr; 2016 Aug; 175():137-43. PubMed ID: 27283463
[TBL] [Abstract][Full Text] [Related]
19. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
